Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
Short telomeres may increase risk of emphysema

Short telomeres may increase risk of emphysema

U.S. Senators introduce Pulmonary Fibrosis Research Enhancement Act

U.S. Senators introduce Pulmonary Fibrosis Research Enhancement Act

AJMS summarizes developments related to idiopathic pulmonary fibrosis

AJMS summarizes developments related to idiopathic pulmonary fibrosis

Enrollment commences in InterMune's Esbriet Phase 3 study for IPF

Enrollment commences in InterMune's Esbriet Phase 3 study for IPF

Study confirms link between delayed access to tertiary care for IPF, higher risk of death

Study confirms link between delayed access to tertiary care for IPF, higher risk of death

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

Amira to present AM152 preclinical data in fibrotic disease at ATS Annual Meeting

Amira to present AM152 preclinical data in fibrotic disease at ATS Annual Meeting

Promedior's PRM-151 clinical data in idiopathic pulmonary fibrosis to be presented at ATS 2011

Promedior's PRM-151 clinical data in idiopathic pulmonary fibrosis to be presented at ATS 2011

New genetic discovery in Pulmonary Fibrosis

New genetic discovery in Pulmonary Fibrosis

Promedior to present PRM-151 study data in age-related macular degeneration at ARVO meeting

Promedior to present PRM-151 study data in age-related macular degeneration at ARVO meeting

Genetic variation associated with MUC5B gene may increase risk of developing Pulmonary Fibrosis

Genetic variation associated with MUC5B gene may increase risk of developing Pulmonary Fibrosis

New study finds no significant benefit of bosentan against IPF

New study finds no significant benefit of bosentan against IPF

MicroRNAs may play a key role in future medicine

MicroRNAs may play a key role in future medicine

CPF applauds new guidelines for treatment of idiopathic pulmonary fibrosis

CPF applauds new guidelines for treatment of idiopathic pulmonary fibrosis

EC grants marketing authorization for InterMune's Esbriet to treat IPF

EC grants marketing authorization for InterMune's Esbriet to treat IPF

Acute viral infection does not appear to cause exacerbation of IPF

Acute viral infection does not appear to cause exacerbation of IPF

Single donor gifts lungs for two lung transplants

Single donor gifts lungs for two lung transplants

Registration open for idiopathic pulmonary fibrosis healthcare summit

Registration open for idiopathic pulmonary fibrosis healthcare summit

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

Study shows beneficial anti-fibrotic effects of Pentraxin-2 in idiopathic pulmonary fibrosis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.